Johnson & Johnson (J&J) has reported sales of $23.3bn in the third quarter (Q3) of 2021, a rise of 10.7% compared to $21.08bn in the same quarter last year.
For the quarter, the net earnings were recorded at $3.67bn, an increase of 3.2% against $3.55bn during last year’s quarter.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn the US, the reported sales of the company rose by 7.9% to $11.96bn in Q3 compared to $11.08bn last year.
During the same quarter, international and worldwide sales grew by 13.8% and 10.7%, respectively.
The pharmaceutical segment of J&J recorded a 13.8% increase in sales to $12.99bn in the third quarter of 2021 versus $11.42bn in the same quarter a year ago.
Furthermore, the pharmaceutical global operational sales increased 13.8%, which excluded the net effect of acquisitions and divestitures.
Drugs such as Darzalex, Stelara, Tremfya and the company’s Covid-19 vaccine drove the growth in sales.
J&J reported that a rise of 8% in sales from $6.64bn in Q3 2021 as against $6.15bn last year were recorded in the medical devices segment.
J&J increased its 2021 full-year guidance for operational sales from $92.8bn to $93.3bn including Covid-19 vaccine sales from $92.5bn to $93.3bn in July.
The diluted adjusted EPS was also raised to $9.77 to $9.82 from $9.60 to $9.70.
Johnson & Johnson chairman and CEO Alex Gorsky said: “Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health.
“In the face of evolving marketplace dynamics resulting from the effects of Covid-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of our stakeholders while also successfully investing in a pipeline of innovation and key commercial platforms to drive our future growth.”
In July, J&J recorded sales of $23.31bn in the Q2 of 2021, an increase of 27.1% versus $18.33bn in Q2 last year.
